Summary
Danaher Corporation (DHR) reported its first quarter 2026 results, showcasing a 3.5% increase in total sales to $5.95 billion, driven by strong performance in the Biotechnology segment and a positive currency translation impact. Core sales, excluding currency effects and acquisitions, grew by a modest 0.5%, indicating underlying business growth that was slightly tempered by a decline in the Diagnostics segment. Net earnings rose to $1.0 billion, or $1.45 per diluted share, up from $954 million, or $1.32 per diluted share, in the prior year, primarily attributed to increased core sales and reduced net interest expense. The company highlighted robust growth in its Biotechnology segment, with sales up 11.5% (7.0% core sales growth), driven by consumables and bioprocessing demand. The Life Sciences segment saw a 3.5% total sales increase (0.5% core sales growth), supported by filtration and consumables. However, the Diagnostics segment experienced a 1.5% total sales decline (4.0% core sales decline), largely due to reduced demand for respiratory tests and pricing impacts in China. Management remains focused on strategic acquisitions, including the pending Masimo acquisition, while navigating global economic uncertainties and geopolitical tensions.
Financial Highlights
50 data points| Revenue | $5.95B |
| Cost of Revenue | $2.36B |
| Gross Profit | $3.59B |
| R&D Expenses | $387.00M |
| SG&A Expenses | $1.86B |
| Operating Income | $1.34B |
| Net Income | $1.03B |
| EPS (Basic) | $1.45 |
| EPS (Diluted) | $1.45 |
| Shares Outstanding (Basic) | 707.90M |
| Shares Outstanding (Diluted) | 711.20M |
Key Highlights
- 1Total sales for the first quarter of 2026 increased by 3.5% to $5.95 billion, driven by a 3.0% favorable impact from currency exchange rates.
- 2Core sales, which exclude currency translation and acquisitions, grew by 0.5%, reflecting a mixed performance across segments.
- 3Net earnings increased to $1.0 billion ($1.45 per diluted share) from $954 million ($1.32 per diluted share) in the prior year's comparable period.
- 4The Biotechnology segment demonstrated strong growth, with total sales up 11.5% and core sales up 7.0%, driven by consumables and bioprocessing demand.
- 5The Diagnostics segment experienced a 1.5% decrease in total sales and a 4.0% decline in core sales, primarily due to reduced demand for respiratory tests and pricing pressures in China.
- 6Operating profit margin improved by 40 basis points to 22.6%, benefiting from higher core sales and operational leverage, partially offset by acquisition-related transaction costs.
- 7The company is progressing with the pending acquisition of Masimo Corporation, which incurred transaction costs impacting the Diagnostics segment's operating profit margin.